

Antimicrobial profile of *Salmonella enterica* serotype Choleraesuis from free-range swine in Kakamega fish market, western Kenya

David M Onyango¹, Violet M Ndeda¹, Sarah A Wandili¹, Sifuna A Wawire², Philip Ochieng¹

¹ Department of Zoology, Molecular Microbiology and Biotechnology Laboratory, Maseno University, Maseno, Kenya

² Department of Biological Sciences, Masinde Muliro University, Kakamega, Kenya

Abstract

Introduction: *Salmonella enterica* subspecies *enterica* serovar Choleraesuis is a host-adapted, facultative, intracellular pathogen that causes swine paratyphoid. Its antimicrobial resistance presents a challenge to feed manufacturing industries. However, stopping antibiotics in animal feed would have economic implications for the industry.

Methodology: Conventional microbial methods for isolation and identification of *S. Choleraesuis* were employed. The isolates were subjected to screening against 17 antimicrobial agents and genotyping of resistance markers by PCR. The data were then analyzed and presented in percentages.

Results: Phenotypically, 43 out of 95 isolates showed multidrug resistance. Among the 17 antibiotics tested, resistance was observed as follows: sulphonamides (45.2%), nalidixic acid (44.25%), tetracycline (42%), ampicillin (36.8%), erythromycin (34.7%), carbenicillin (31.5%), chloramphenicol (28.4%), gentamicin (27.3%), kanamycin (24.2%), spectinomycin (21%), sulfamethoxazole-trimethoprim (16.8%), streptomycin (12.6%), cephalothion (8.4%), ofloxacin (5.2%), ciprofloxacin (4.2%), and norfloxacin (4.2%). Fifty-two isolates were susceptible to the antimicrobial agents tested. A total of 3.1% of the isolates had the integron gene pattern combination of *dfrA2-aadA2* (2100 bp), *dfrA12* (2100 bp); 4.2% had *dfrA12-aadA2-sulI* (2100 bp); 2.1% had *dfrA12-aadA2* (2100 bp); and 1% had *dfrA2-aadA2-sulI* (2100 bp), *oxa1-aadA2* (1500 bp), *dfrA12-aadA2-sulI*, and *bla_{PSE}* (2100 bp).

Conclusions: The isolated *S. Choleraesuis* were resistant to more than 10% of the antimicrobial agents used in this study. Appropriate surveillance is warranted to gain more information about the epidemiology, as stopping antibiotics in animal feed would have economic implications for the industry.

Key words: antimicrobial resistance; integron; swine; *Salmonella Choleraesuis*.

J Infect Dev Ctries 2014; 8(11):1381-1390. doi:10.3855/jidc.3861

(Received 10 June 2013 – Accepted 11 August 2014)

Copyright © 2014 Onyango *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Swine are prone to infection by a variety of serotypes of *Salmonella*. Some infected swine display clinical symptoms of salmonellosis, while others are asymptomatic. However, even in the absence of symptoms, contamination of pork products can occur [1], causing a public health risk when pork is consumed. *Salmonella* outbreaks of a common single foodborne origin have been reported. It has been reported that, as a result of a high degree of genetic diversity, all *Salmonella* isolates can be classified into a single species (formally called *S. Choleraesuis*), which can be sub-classified into seven subgroups based on DNA similarity and host range. Subgroup 1 contains all the serotypes pathogenic for humans [2], except for rare human infections with group IIIa and IIIb, formally designated *S. arizonae*. Here we use the more accepted nomenclature *S. enterica* subspecies

enterica rather than *S. Choleraesuis* subgroup 1 serovar Choleraesuis (*S. Choleraesuis*) [3]. The most common serovars in swine are *S. enterica* subspecies *enterica* serovar Typhimurium (*S. Typhimurium*), *S. Derby*, and *S. Choleraesuis* [3-5]. *S. Choleraesuis* has been reported to be host-adapted and most commonly isolated from swine [4]. According to Berends *et al.* [6], there is a significant correlation between the number of swine harboring *Salmonella* while alive and the number of *Salmonella*-infected carcasses. Studies have shown that most *S. Choleraesuis* isolated from humans and swine exhibit the same or similar DNA fingerprints, an indication of cross-infection from pigs to humans through food, water, or eating of pigs' offal by the local population. Studies in Canada and the United Kingdom show that serotype Choleraesuis is infrequently isolated from human sources [7-9]. However, in Thailand between 1988 and 1993,

serotype *Choleraesuis* was the tenth most common serotype that caused salmonellosis in humans and was the second most common in Taiwan [10-12]. Two biotypes of *S. Choleraesuis* have been reported based on their biochemical activity on triple sugar iron (TSI) agar; these are *Choleraesuis sensu stricto*, which is H₂S negative, and *Kunzendorf*, which is H₂S positive. *Choleraesuis* incidence is increasing in other parts of the continent, *e.g.*, in Japan, Taiwan, and Turkey [13]. Recent reports suggest that critical forms of antibiotic resistance arise in human pathogens as a result of certain antibiotics being used in food-producing animals, and that such resistance can be transmitted to humans via the food chain [14-20]. As evidenced by reports from other studies, the importance of the use of antimicrobials in swine, poultry, and beef cannot be underestimated and presents considerable financial constraints to the gross domestic product (GDP) of affected countries [19-21]. However, despite the restriction against the use of antimicrobial agents in agriculture [22], resistance genes have been reported [21,22], a fact supported by studies conducted at the genome level, which indicates that even if antimicrobials are withdrawn from use, the disappearance of resistant variants from the population might be slower than anticipated [21]. This could be linked to compensatory mutations conferring fitness to resistant organisms [23]. Though there are a multitude of studies describing the frequency of antimicrobial resistance to different classes of antimicrobial agents, information on the association of resistance with antimicrobial use in food animals is often controversial. Nonetheless, it is believed that risk factors due to *Salmonella* infection both clinically or environmentally are associated with temperature variability, poor hygienic practices, and above-median feed conversion efficiency [24]. Besides antimicrobial resistance due to mutation of chromosomally located genes, acquired resistance genes might also be integrated into the chromosome, presenting one of the major emerging problems among foodborne bacterial pathogens [25]. On the other hand, 95% of antimicrobial resistance genes are encoded on plasmids, which facilitate horizontal transfer of genes within microorganisms that harbor integration systems [26]. Class 1 integrons make up most of the integrons found in clinical isolates and are strongly associated with multiple-antibiotic resistance. By the end of 1995, this aspect of resistance was found to point to various class 1 integron genes [16,25,27,28]. An efficient route of acquisition and vertical and horizontal dissemination of resistance determination is

through mobile elements including plasmids, transposons, and gene cassettes in integrons [29,30]. It has been reported that clonal expansion of integron-bearing *S. enterica* would account for the occurrence of a particular genetic lineage with a specific integron in a variety of regions, while horizontal gene transfer would account for the existence of identical integrons in isolates of different genetic lineages [31-34]. Over 70 different gene cassette encoding proteins that confer resistance to many antibiotic families have been characterized within integrons, including enzymes that inactivate antibiotics (β -lactams, aminoglycosides, chloramphenicol), metabolic by-passes (trimethoprim), and efflux systems (chloramphenicol) [29,35]. Most of the *attC* sites of integron-associated resistance gene cassettes identified to date share only slight homologies. Thus, regular surveillance of *S. Choleraesuis* in domestic animals could be helpful for human health. To explore the roles of clonal expansion and horizontal gene transfer in the dissemination of antimicrobial drug resistance caused by class 1 integrons, we investigated the integron structure and serotypes of 95 MDR non-typhoidal *S. enterica* isolates from swine in western Kenya.

Methodology

Samples

Approximately 200 fecal samples from individual swine described as free-range were obtained from a fish market in Kakamega municipality, western Kenya (0°17'N 34°45'E) between 2009 and 2010. During collection, the fecal samples were picked with sterilized wooden spatulas; sterile swabs were used to collect fecal samples. A small piece (\approx 1gm) was enriched in 10 mL of tetrathionate broth (Himedia Labs, Mumbai, India) and rappaport-vassiliadis (RV) (Himedia, India) and incubated at 37°C for tetrathionate broth and 42°C for rappaport vassiliadis for 20 hours under anaerobic conditions in the Molecular Microbiology and Biotechnology Laboratory of Maseno University. After incubation, a loopful of broth culture was streaked across brilliant green (BG) agar (Himedia, India) and bismuth sulphite (BS) agar and later incubated at 37°C for 12 hours under aerobic conditions. Due to the prevalence of *S. Typhimurium* previously collected in a nearby hospital in this region [35], this study only concentrated on the isolation of *S. Choleraesuis* for the purpose of profiling its existence as a result of data patterns obtained in the previous study [35]. The presumptive *Salmonella* colonies in BG and BS agars were selected and subcultured onto triptic soy agar (TSA) for 12

hours at 37°C under aerobic conditions. The colonies were further confirmed by API (BioMerieux, Marcy l'Etoile, France), followed by serotyping using commercial antiserum (Sigma-Aldrich, St. Louis, USA), and the resulting serotype was identified using the Kauffman-White serotyping scheme. The isolates were classified into biotypes by confirming their H₂S production capacity in sulfide-indole-motility (SIM) media (Fluka, Sigma-Aldrich).

Antimicrobial susceptibility of the S. Choleraesuis isolates

Antimicrobial susceptibility of the isolates (95 *S. Choleraesuis*) was examined by the Clinical and Laboratory Standards Institute (CLSI) disk diffusion method [36,37]. The isolates were spread on Mueller-Hinton agar (Fluka, Sigma-Aldrich) plates using a dry-heat sterilized chrome wire loop [38]. Each isolate was first tested against a panel of 17 antimicrobial agents. The antimicrobials concentrations were ampicillin (10 µg), amoxicillin-clavulanic acid (25 µg), gentamicin (10 µg), cephalothin (30 µg), chloramphenicol (30 µg), erythromycin (15 µg), tetracycline (30 µg), sulfamethoxazole-trimethoprim (23.75 µg), norfloxacin (10 µg), ciprofloxacin (5 µg), ofloxacin (5 µg), nalidixic acid (30 µg), sulfonamides (300 µg), streptomycin (10 µg), carbenicillin (100 µg), kanamycin (30 µg), and streptomycin (10 µg). *Escherichia coli* ATCC 25922 was used as a control strain. The breakpoint for antimicrobial drugs was based on the guidelines provided by the CLSI [38]. Isolates with intermediate values were considered susceptible for the purposes of this study, so as not to overestimate the extent of resistance.

Genotypic isolation and analysis of antibiotic resistance genes

Discrete *Salmonella* colonies isolated from overnight cultures at 37°C were transferred into 3 mL TSA tubes and incubated for eight hours. A total of 10 µL of the bacterial cell dilution (approximately 10⁵ CFU/10 µL) was lysed by heating at 100°C for 10 minutes in a water bath. Next, 5 µL of the bacterial cell dilution (approximately 10⁵ CFU/10 µL) was aliquoted and mixed with 10 µL PCR buffer (10 mM Tris-HCl, pH 8.8; 1.5 mM MgCl₂; 50 mM KCl; and 0.1% Triton X-100), 200 pmol each of dATP, dGTP, dCTP, dTTP (Boehringer Mannheim, Germany), 50 pmol each of the PCR primer, and 0.2 U ProTaq polymerase. The cycling conditions were as follows: 94°C for 5 minutes followed by 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds,

and a final extension step at 72°C for 10 minutes. The antibiotic resistance genes under investigation were the *pse* group (ampicillin), *dfpA2* (sulfamethoxazole-trimethoprim or trimethoprim), *oxa1* (ampicillin), *aadA1a* (streptomycin and spectinomycin), *aphA* (kanamycin), *cmlA* (chloramphenicol), *sul* (sulfonamide), *aadB* (gentamicin), and *cat* (chloramphenicol) (Table 1). Amplicons were then loaded onto a casted 2% agarose gel (Eurobio, Les Ulis, France) and run in tris-borate-EDTA buffer (89 mmol l⁻¹ Tris pH 8.3, 89 mmol l⁻¹ borate and 2 mmol l⁻¹ EDTA). The gel was stained with ethidium bromide solution (0.5 µg mL⁻¹) and run at 135 V for 25 minutes, then photographed under UV (Daiham Scientific, Wonju, Korea).

Integron analysis

Resistance to sulfonamides is commonly carried on class 1 integrons, suggesting that some or all of the resistance alleles may be integron encoded. The integrons in *Salmonella* strains were detected using primers 5'CS-3'CS and intI1F-intI1R (Table 1) that were specific for integron conserved segments and the class 1 integronase gene. For the primers 5'CS-3'CS, DNA from target bacteria was amplified during 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and a final extension step at 72°C for 2 minutes. PCR conditions for primers intI1F-intI1R were the same as those for the analysis of antibiotic resistance genes. The amplicons were analyzed as previously described.

Results

Phenotypic antibiogram screening of the isolates

A cross-sectional study of antimicrobial resistance among *S. Choleraesuis* and other *Salmonella* isolates (published data elsewhere) was performed within the market study area of Kakamega municipality. The resistance was categorized according to the number of resistant antibiotics hereby presented in categories A through M (Table 2). Category E had the highest number of strains that displayed a broad antimicrobial resistance spectrum; these strains were resistant to tetracycline, sulfamethoxazole-trimethoprim, norfloxacin, ciprofloxacin, ofloxacin, nalidixic acid, and sulfonamides (n = 8). This represented 41.1% of the resistant antimicrobial spectrum.

Table 1. Oligonucleotide sequences used in the amplification of integron and antimicrobial resistance genes in *S. Choleraesuis*

Primers	Sequence	Targeted gene	Specific antibiotic resistance	Product size (bp)	Accession no.	Reference
5'CS	GGC ATC CAA GCA GCA AGC	integron	-	-	M73819	[64]
3'CS	AAG CAG ACT TGA CCT GAT					
intI1F	CCC TCC CGC ACG ATG ATC	integrase I	-	280	M73819	[65]
intI1R	TCC ACG CAT CGT CAG GC					
PSE G1	ACC GTA TTG AGC CTG ATT TA	PSE group (PSE-1, PSE-4,CARB-3)	Ampicillin	321		[66]
PSE G2	ATT GAA GCC TGT GTT TGA GC					
dfr12-F	ACT CGG AAT CAG TAC GCA	<i>dfrA12</i>	Trimethoprim	462	AF175203	[20]
dfr12-B	GTG TAC GGA ATT ACA GCT					
oxa1-F	AGC AGC GCC AGT GCA TCA	<i>oxa1</i>	Ampicillin	708	AJ009819	[67]
oxa1-R	ATT CGA CCC CAA GTT TCC					
ant-3'-1aF	GTG GAT GGC GGC CTG AAG CC	<i>aadA1a</i>	Streptomycin,	527	M10241	[67]
ant-3'-1aB	ATT GCC CAG TCG GCA GCG		Spectinomycin			
aphA-1L	TTA TGC CTC TTC CGA CCA TC	<i>aphA</i>	Kanamycin	489	U63147	[68]
aphA-1R	GAG AAA ACT CAC CGA GGC AG					
cat-F	CCT GCC ACT CAT CGC AGT	<i>cat</i>	Chloramphenicol	632	U46780	[20]
cat-B	CCA CCG TTG ATA TAT CCC					
aadB-F	GAG CGA AAT CTG CCG CTC TGG	<i>aadB</i>	Gentamicin	310	AF078527	[69]
aadB-B	CTG TTA CAA CGG ACT GGC CGC					
cmlA-F	TGTCATTTACGGCATACTCG	<i>cmlA</i>	Chloramphenicol	435	M64556	[20]
cmlA-B	ATCAGGCATCCC ATT CCC AT					
sul1-F	CCT CGA TGA GAG CCG GCG GC	<i>Sul</i>	Sulfonamide	437		[67]
sul1-R	GCA AGG CGG AAA CCC GCG CC					
QS-1	ATG AAA GGC TGG CTT TTT CTTG	<i>qac/sul1</i>		850		[70]
QS-2	TGA GTG CAT AAC CAC CAG CC					



Table 2. Antibiograms of *Salmonella* Choleraesuis isolates from swine in Kakamega municipality, western Kenya

Antibiogram tested (N = 17)	No. in the category	No. of resistant antibiograms (%)	Categories
ENaSu	1	3 (17.6%)	A
ETNaSu	1	4 (23.5%)	B
ETNaSus	5	5 (29.4%)	C
AmpGmENaSu	3	6 (35.3%)	D
TSxtNorCipOfiNaSu	8	7 (41.1%)	E
GmCETNaSuCbK	4	8 (47.1%)	F
AmpGmETNaSuSCbK	4	9 (52.9%)	G
AmpGmCfCETNaSuScbK	5	10 (58.8%)	H
AmpGmCfCETNaSuSCbK	5	11 (64.7%)	I
AmpGmCfCETSxtNaSuSpSCb	3	12 (70.6%)	J
AmpGmCfCETSxtNaSuSpSCbK	1	13 (76.5%)	K
AmpGmCTSxtNorCipOfiNaSuSpSCbK	1	14 (82.4%)	L
AmpGmCfCETSxtNorCipOfiNaSuSpSCb	2	15 (88.2%)	M

Amp: ampicillin; Gm: gentamicin; Cf: cephalothion; C: chloramphenicol; E: erythromycin; T: tetracycline; Sxt: sulfamethoxazole-trimethoprim; Nor: norfloxacin; Cip: ciprofloxacin; Ofi: ofloxacin; Na: nalidixic acid, Su: sulfonamides; Sp: streptomycin; S: spectinomycin; Cb: carbenicillin; K: kanamycin

Table 3. Phenotypes of antimicrobial resistance analysis for *S. Choleraesuis* isolates

Antimicrobial class	% of resistant strains (n = 95)
Penicillins	
Ampicillin	89.5%
Amoxicillin-clavulanic acid	0%
Carbenicillin	87.4%
Aminoglycosides	
Gentamicin	67.4%
Streptomycin	70.6%
Kanamycin	80%
Cephalosporin I	
Cephalothin	7.4%
Phenicol	
Chloramphenicol	75.8%
Tetracycline	
	93.7%
Sulfonamides and potentiated sulfonamides	
Trimethoprim-sulfamethoxazole	32.6%
Sulfonamides	100%
Quinolones and fluoroquinolones	
Nalidixic acid	100%
Ciprofloxacin	21.1%
Norfloxacin	21.1%
Ofloxacin	24.2%
Macrolides	
Erythromycin	80%
Aminocyclitols	
Spectinomycin	31.6%

Category I had five isolates exhibiting resistance to ampicillin, gentamicin, cephalothion, chloramphenicol, erythromycin, tetracycline, nalidixic acid, sulfonamides, streptomycin, carbencillin, and kanamycin (64.7%); category H had five isolates resistant to ampicillin, gentamicin, cephalothion, chloramphenicol, erythromycin, tetracycline, nalidixic acid, sulfonamides, streptomycin, carbencillin, and kanamycin (58.8%); category C had five isolates resistant to erythromycin, tetracycline, nalidixic acid, sulfonamides, and streptomycin (29.4%); and category G had four isolates exhibiting resistance to ampicillin, gentamicin, erythromycin, tetracycline, nalidixic acid, sulfonamides, streptomycin, carbencillin, and kanamycin (52.9%) (Table 2). There were a number of isolates resistant to a combination of ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline. Among these isolates, resistance was highest to nalidixic acid (100%), followed by sulfonamides (100%), tetracycline (93.7%), ampicillin 89.5%), carbencillin (87.4%), kanamycin (80%), erythromycin (80%), chloramphenicol (75.8%), streptomycin (70.6%), and gentamicin (67.4%) (Table 3). Though the frequency of resistance is low, resistance to these antimicrobial agents, mainly cephalosporins and trimethoprim/sulfamethoxazole, is significant since these are some of the last-resort agents for human infection [39].

Integron detection and characterization

It should be noted that due to financial constraints of the project, the team could not proceed with the study of the *spv* virulence genes in the isolates to confirm the presence of a plasmid; this will be pursued in future studies. In order to confirm the phenotypic basis of resistance, a number of resistance gene were sorted; among them were those for beta-lactam inhibitors (*bla_{PSE-1}*, *bla_{TEM}* and *oxa1*), sulphonamide resistance (*sul1* and *sul2*), chloramphenicol acetyltransferase (*cat* and *cmlA*), kanamycin resistance (*aphA*), aminoglycoside adenyltransferase (*aadA1a*), and gentamicin (*aadB*) (Table 1). The isolates displayed a myriad of resistance gene patterns; 31.6% (30/95) displayed the presence of *dfrA12* gene, 1.1% (1/95) displayed the *bla_{PSE-1}* gene, 30.5% (29/95) the *aadA1a* gene, 86.3% (82/95) the *aphA* gene, 1.1% (1/95) the *oxa1* gene, 30.5% (29/95) the *cmlA* gene, while 27.4% (26/95) displayed the *qac/sul1* gene. Integrons ranging between 650 bp and 2100 bp and integrase 1 genes of 280 bp were amplified in 32.6% (31/95) of isolates, with the 1500 bp integron size

being encoded for streptomycin-spectinomycin and β -lactam resistance (*i.e.*, with the *oxa1-aadA1a* gene cassettes), while the rest were of 2100 bp size, which encode for the resistance to trimethoprim-sulfonamides and β -lactams.

Discussion

S. Choleraesuis is reported to have evolved through gene deletion and sequence alternations to become a very efficient and successful pathogen among non-typhoidal *Salmonella*, particularly with regard to its pathogenicity and antimicrobial resistance [3,29]. These deletions and sequence alterations bring out ESBL and *ampC* genes, and *qnr*-related resistance due to their mobile nature, making the treatment for invasive *Salmonella* infections challenging [40]. The abundant use of antibiotics in human and veterinary medicine and in food production has led to antimicrobial drug resistance [41]. Several authors have implicated the misuse of antimicrobials or the mobile genetic elements of bacteria (plasmids, transposons, and integrons) as the cause of widespread antimicrobial resistance [42-44], but this has now changed due to the generic nature by which different strains acquire the resistance genes. The ability of integrons to excise and integrate resistance gene cassettes from the environment or other bacteria have given them a cardinal role in antimicrobial resistance in bacteria [45-48,23]. Integrons have been identified among clinical isolates, in farm animals, and in aquatic environments [49]. In this regard, in order to better understand antimicrobial drug resistance gene mechanisms in *S. Choleraesuis*, this study characterized the class 1 integrons and genetic mechanisms associated with 43 out of 95 *Salmonella*-positive isolates obtained from within the surrounding fish market in Kakamega municipality, western Kenya. Out of 95 *Salmonella* isolates, 43 were found to be multidrug resistant, with the rest having single or double drug resistance (unpublished data). Other authors [50,51] have reported in Taiwan the existence of *S. Choleraesuis* that is resistant to multiple antibiotics, including ciprofloxacin and ceftriaxone, through various mechanisms. Apart from the different mechanisms – production of hydrolytic enzymes to destroy the antibiotic surrounding the environment, mutations in the specific genes to escape from the action of antibiotics, decreased outer membrane permeability to prevent antibiotics from entering the bacterial cell itself, and efflux systems to exclude antibiotics before they become effective – other mechanisms have been described [51,52]. Production

of enzymes due to extended-spectrum cephalosporinases has been observed in *S. Choleraesuis* resistance, and most of the isolates in this study were found to display this property with cephalothin (Table 3) [51]. This is an indication that the isolates could be harboring cefotaxime-hydrolyzing β -lactamases (CTX-M types) or CMY-2 AmpC β -lactamase that could hydrolyze cephalosporins normally transferred through conjugative plasmids, transposons, or integrons [52,53]. This is supported by the fact that resistance to β -lactams in *S. enterica* is primarily caused by the production of acquired β -lactamases [54], with TEM-1, PSE-1, and OXA-1 having been described as the enzymes most frequently related to ampicillin and amoxicillin/clavulanate resistance. Thus, the resistance pattern of amoxicillin-clavulanic acid, carbenicillin, and ampicillin observed in this study resulted from the β -lactamase enzyme [55]. The spread of resistant determinant genes that are clonally disseminated and horizontally transferred was also observed in β -lactam penicillins (ampicillin, amoxicillin-clavulanic acid, carbenicillin), to which over 80% of the isolates showed resistance, except amoxicillin-clavulanic acid, to which the isolates did not have any resistance. This is an indication of the existence of *bla*_{PSE1}, *bla*_{TEM}, and *oxal* in the group of *bla*_{CMY-2} that are plasmid oriented (Table 3) [56,57]. This is an indication for the presence of plasmid-mediated β -lactamases including TEM-type penicillinase, inhibitor-resistant TEM (IRT) β -lactamase, and oxacillinase-1 (OXA-1) β -lactamase [57]. Resistance to quinolones and fluoroquinolones (nalidixic acid, ciprofloxacin, norfloxacin, and ofloxacin) observed in these isolates was indicative of a quinolone resistance gene being displayed (Table 3). This finding is supported by that of Ricci *et al.* [58], which found that *Salmonella* resistance to fluoroquinolones in most cases involved mutations in the quinolone resistance-determining regions of the DNA genes, active efflux (AcrAB efflux), and decreased outer membrane permeability strains [58,59]. In this study, the isolates could have harbored either *gyrA*, *gyrB*, *parC*, or *parE* genes as a result of point mutation in fluoroquinolones, though all these genes were not studied due to restricted funding; however, equal resistance was observed to ciprofloxacin, which has been shown to be anchored in mutations that give rise to the substitution of phenylalanine for serine at position 83 and asparagine for aspartic acid at position 87 in *gyrA* as documented by other authors [50,51,60-62]. The same trend of resistance has also been observed within sulfonamides

and potentiated sulfonamides, with sulfonamides being the most resistant [60-62]. This was based on the amplification of *dfr12*, *qac/sul1*, and *sul1*, which are among the Tn21 class 1 integron gene cassettes [63]. These translated to streptomycin and sulfamethoxazole phenotypic resistance. The *cmlA* responsible for chloramphenicol resistance found in Tn1696 was also amplified in the isolates [60]. Overall, the most potent drug of choice in the management of *S. Choleraesuis* was amoxicillin-clavulanic acid. The plasmid-encoding kanamycin resistance was through the aminoglycosides phosphotransferases *aphAa* gene, which was detected in 82/95 isolates.

In conclusion, the emergence of *S. Choleraesuis* that is resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, gentamicin, and, notably, fluoroquinolones, was observed in this busy cosmopolitan marketplace where traders converge to sell their merchandise. Concern has been raised about the use of these agents for the empirical treatment of systemic infection caused by this organism in both humans and animals. In view of the serious implications of this situation, the chain of transmission and mechanism of resistance should be studied further to discern the possible resistance genes circulating within this environment in order to assist in clinical management of *S. Choleraesuis* in the region. It would be also important to obtain an aerial view of genes possessed by this particular serotype of *S. Choleraesuis* to corroborate the findings with those of human clinical studies within the region and to solve the worrying clinical problems by genotyping.

Acknowledgements

We acknowledge the municipal council authorities of Kakamega County for allowing us to collect pig droppings (stools) from the market and its surrounding areas. We also thank the public health department of the country for the assistance they gave us towards realizing our goal for the project. We thank Maseno University for giving us the necessary support needed within the university premises. Lastly we thank Prof. Dr. David M. Onyango for allowing us to use his laboratory reagents and supplies from his many funded projects.

References

1. Aarestrup FM (1999) Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistance bacteria among food animals. *Int J Antimicrob Agent* 12: 279-285.

2. Bäumler AJ, Tsois RM, Ficht TA, Adams LG (1998) Evolution of host adaptation in *Salmonella enterica*. *Infect Immun* 66: 4579-4587.
3. Cheng-Hsun C, Petrus T, Chishih C, Songnian H, Quiyu B, Jun Y, Yun-Ying C, Hsin-Shin W, Ying-Shieng L (2005) The genome sequence of *Salmonella enterica* serovar Choleraesuis, a highly invasive and resistant zoonotic pathogen. *Nucleic Acids Research* 33: 1690-1698
4. Mark A, John W, Francois-Xavier W, Sathesh N, Zhemin Z, Vartul S, Mary GK, Gordon D, Lee HH, Sylvain B, the enterica MLST study group (2012) Multilocus sequence typing as a replacement for serotyping in *Salmonella enterica*. *PLoS Pathogens*, 8:e1002776:1-9.
5. Wei-Qiao L, Ye F, Yan W, Quing-Hua Z, Fang C, Ji-Tao G, Yi-HP, Yan J, Young-Guo L, Song-Nian H, Randal NJ, Gui-Rong L, Shu-lin L (2009) *Salmonella* paratyphi C: Genetic Divergence from *Salmonella* Choleraesuis and pathogenic convergence with *Salmonella typhi*. *PLoS One* 4 e450:1-8.
6. Berends BR, Van Knappen F, Snijders JM, Mossel DA (1997) Identification and quantification of risk factors regarding *Salmonella* spp. on pork carcasses. *Int J Food Microbiol* 36: 199-206.
7. Barrel RA (1987) Isolations of salmonellas from humans and foods in the Manchester area: 1981–1985. *Epidemiol Infect* 3:277–284.
8. Khakhria R, Johnson W (1995) Prevalence of *Salmonella* serotypes and phage types in Canada. *Southeast Asian J Trop Med Public Health* 26: 42–44.
9. Briggs CE, Fratamico PM (1999) Molecular characterization of an antibiotic resistance gene cluster of *Salmonella typhimurium* DT104. *Antimicrob Agents Chemother* 43: 846-849.
10. Bangtrakulnonth A, Pornruangwong S, Kusum M, Damrongwatanapokin T, Saitanu K (1995) Prevalence of *Salmonella* in humans during 1988–1993. *Southeast Asian J Trop Med Pub Health* 26: 52–53.
11. Chen YH, Peng CF, Tsai JJ, Hwang KP, Lu PL, Cheng HH, Chen TP (1999) Epidemiological study of human salmonellosis during 1991–1996 in southern Taiwan. *Kaohsiung J Med Sc* 15:127–136.
12. Chiu CH, Lin TY, Gu JT (1999) Predictors for extraintestinal infectious of non-typhoidal *Salmonella* in patients without AIDS. *Int J Clin Pract* 53: 161–164.
13. Cheng-Hsun C, Lin-Hui S, Chishih C (2004) *Salmonella enterica* Serotype Choleraesuis: Epidemiology, Pathogenesis, Clinical Disease, and Treatment. *Clin Microb Rev* 17: 311–322
14. Bolton LF, Kelley LC, Lee MD, Fedorka-Cray PJ, Maurer JJ (1999) Detection of multi-drug resistant *Salmonella enterica* serotype typhimurium DT104 based on a gene which confers cross-resistance to florfenicol and chloramphenicol. *J Clin Microbiol* 37: 1348–1351.
15. Boyd D, Peters GA, Cloeckert A, Sidi Boumedine K, Chaslus-Dancla E, Imberechts H (2001) Complete nucleotide sequence of a 43-kilobase genomic island associated with the multidrug resistance region of *Salmonella enterica* serovar Typhimurium DT104 and its identification in phage type DT120 and serovar Agona. *J Bacteriol* 183: 5725–5732.
16. Boyd DA, Peters GA, Ng LK, Mulvey MR (2000) Partial characterization of a genomic island associated with the multidrug resistance region of *Salmonella enterica* Typhimurium DT104. *FEMS Microbiol Lett* 189: 285–291.
17. Briggs CE, Fratamico PM (1999) Molecular characterization of an antibiotic resistance gene cluster of *Salmonella* Typhimurium DT104. *Antimicrob Agents Chemother* 43: 846.
18. Davies JE (1997) Origins, acquisition, and dissemination of antibiotic resistance determinants. In: Chadwick DJ, Goode J, editors. *Antibiotic resistance: origins, evolution, selection and spread*. New York: John Wiley and Sons Inc. 15–27.
19. Fluit AC, Schmitz FJ (1999) Class I integrons, gene cassettes, mobility, and Epidemiology. *Eur J Clin Microbiol Infect Dis* 18: 761-770.
20. Guerra B, Soto SM, Arguelles JM (2001) Multidrug resistance is mediated by large plasmids carrying a class I integron in the emergent *Salmonella enterica* serotype. *Antimicrob Agents Chemother* 45: 1305-1308.
21. Griffith RW, Schwartz KJ, Meyerholz DK (2006) Salmonellosis. In: Straw BE, Zimmerman JJ, D'Allaire S, Taylor DJ, editors. *Disease of Swine*. Ames: Blackwell Publishing. 639-674.
22. Schwarz P, Kich JD, Kolb J, Cardoso M (2011) Use of an avirulent live *Salmonella* Choleraesuis vaccine to reduce the prevalence of *Salmonella* carrier pigs at slaughter. *Veterinary Record* 169: 553.
23. Krauland M, Marsh W, Paterson DL, Harrison LH (2009) Integron-mediated Multidrug Resistance in a Global Collection of Non typhoidal *Salmonella enterica* Isolates. *Emerg Infect Dis* 15: 388–396.
24. Mazel D and Davies J (1998) Antibiotic resistance. The big picture. *Adv Exp Med Biol* 456: 1-6.
25. McDonald LC, Chen MT, Lauderdale TL, Ho M (2001) The use of antibiotics critical to human medicine in food-producing animals in Taiwan. *J Microbiol Immunol Infect* 34: 97-102.
26. Molbak K, Baggesen DL, Aarestrup FM, Ebbesen JM, Engberg J, Frydendahl K, Gerner-Smidt P, Peterant AM, Wegener HC (1999) An outbreak of multidrug-resistant, quinolone-resistant *Salmonella enterica* serotype typhimurium DT104. *N Engl J Med* 341: 1420-1425.
27. Recchia GD, Hall RM (1995) Gene cassettes: a new class of mobile element. *Microbiol* 141: 3015-3027.
28. Stobberingh E, Van den BA, London N, Driessen C, Top J, Willems R (1999) Enterococci with glycopeptide resistance in turkeys, turkey farmers, turkey slaughterers, and (sub) urban residents in the south of The Netherlands: evidence for transmission of vancomycin resistance from animals to humans? *Antimicrob. Agents Chemother* 43: 2215-2221.
29. Khan AA, Ponce E, Nawaz MS, Cheng CM, Khan JA, West CS (2008) Imported Seafood among *Salmonella* Strains Isolated from I Integron Resistance Gene Cassettes Identification and Characterization of Class. 10.1128/AEM.02054-08. *Appl Environ Microbiol* 75: 1192.
30. Mei-Feng L, Yen-Hsu C, Chien-Fang P (2009) Molecular characterization of class I integrons in *Salmonella enterica* serovar Choleraesuis isolates from southern Taiwan. *Intern J Antimicrob Agents* 33: 216–222.
31. Stokes HW, Hall RM (1989) A novel family of potentially mobile DNA elements encoding site-specific gene integration functions: integrons. *Mol Microbiol* 3: 1669-1683.
32. Benbrook C (2001) Impacts of genetically engineered crops on pesticide use in the U.S. - the first sixteen years. *Env Sci Europe* 24: 24
33. Farmer JJ (1999) *Enterobacteriaceae*: introduction and identification. In: Murray P, et al., editors. *Manual of clinical*

- microbiology. 7th ed. Washington, D.C.: American Society for Microbiology. pp. 442–458.
34. Franklin A (1999) Current status of antibiotic resistance in animal production. *Acta Vet Scand Suppl* 92: 23-28.
 35. Onyango MD, Kakai R, Eliud NW, Ghebremedhin B, Konig W and Konig B (2010) Integron-plasmid mediated antibiotic resistance and virulence factors in clinical *Salmonella* enteric serovars in rural western Kenya. *Afr J Pharm and Pharmacol* 4: 490-497.
 36. Clinical and Laboratory Standards Institute (2011) M100-S21 (M2) Disk Diffusion Supplemental Tables. CLSI: Wayne, PA, USA.
 37. Clinical and Laboratory Standards Institute (2002) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, Approved Standard, 2nd edition. CLSI document M31-A2. CLSI: Wayne, PA, USA.
 38. Clinical and Laboratory Standards Institute (2008) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals, Approved Standard, 3rd edition, Informational Supplement. CLSI document M31-A3. CLSI: Wayne, PA, USA.
 39. Levy SB (1998) The challenge of antibiotic resistance. *Sci Am* 278: 46-53
 40. Gunell M, Aulu L, Jalava J, Lukinmaa-Åberg S, Osterblad M, Ollgren J, Huovinen P, Siitonen A, Hakanen AJ (2014) Cefotaxime-resistant *Salmonella enterica* in travelers returning from Thailand to Finland. *Emerg Infect Dis* 20: 1214-1217.
 41. Rodríguez I, Barownick W, Helmuth R, Mendoza MC, Rodicio MR, Schroeter A (2009) Extended-spectrum β -lactamases and AmpC β -lactamases in ceftiofur-resistant *Salmonella enterica* isolates from food and livestock obtained in Germany during 2003–07. *J Antimicrob Chemother* 64: 301–309.
 42. Barlow RS, Pemberton MM, Desmarchelier PM and Gobius KS (2004) Isolation and characterization of integron-containing bacteria without antibiotic selection. *Antimicrob Agents Chemother* 48: 838–842.
 43. Fluit AC and Schmitz FJ (2004) Resistance integrons and super-integrons. *Clin Microbiol Infect* 10: 272–288.
 44. Nogrady N, Paszti J, Piko H, Nagy B (2006) Class I integrons and their conjugal transfer with and without virulence-associated genes in extra-intestinal and intestinal *Escherichia coli* of poultry. *Avian Pathol* 35: 349–356.
 45. Walsh C, Duffy G, Nally POR, McDowell DA, Fanning S (2007) Transfer of ampicillin resistance from *Salmonella* Typhimurium DT104 to *Escherichia coli* K12 in food. *Lett Appl Microbiol* 46: 210–215.
 46. Martin BS, Lapiere L, Cornejo, Bucarey S (2008) Characterization of antibiotic resistance genes linked to class 1 and 2 integrons in strains of *Salmonella* spp. Isolated from swine. *Can J Microbiol* 54: 569–576.
 47. Chiu CH, Wu TL, Su LH, Chu C, Chia JH, Kuo AJ, Chien MS, Lin TY (2002) The emergence in Taiwan of fluoroquinolone resistance in *Salmonella enterica* serotype Choleraesuis. *N Engl J Med* 346: 413–419.
 48. Chui CH, Su LH, Chu C, Chia JH, Wu TL, Lin TY, Lee YS, Ou JT (2004) Isolation of *Salmonella enterica* serotype Choleraesuis resistant to ceftriaxone and ciprofloxacin. *Lancet* 363: 1285-1286.
 49. Villa L, Carattoli A (2005) Integrons and transposons on the *Salmonella enterica* serovar typhimurium virulence plasmid. *Antimicrob Agents Chemother* 49:1194-1197.
 50. Yan JJ, Chiou CS, Lauderdale TLY, Tsai SH, Wu JJ (2005) Cephalosporin and ciprofloxacin resistance in *Salmonella*, Taiwan. *Emerg Infect Dis* 11: 947-950.
 51. Henrik H, Dik M, Kees V, Inger O, Frank MA (2006) β -Lactamases among extended-spectrum β -lactamase (ESBL)-resistant *Salmonella* from poultry, poultry products and human patients in The Netherlands. *J Antimicrob Chemother* 56: 115-121.
 52. Biendo M, Laurans G, Thomas D, Canarelli B, Hamdad-Daoudi F, Rousseau F, Castelain S, Eb F (2005) Molecular characterization and mechanisms of resistance of multidrug-resistant human *Salmonella enterica* serovar Typhimurium isolated in Amiens (France). *Int J Antimicrob Agents* 26: 219-229.
 53. Güerri ML, Aladueña A, Echeita A, Rotger R (2004) Detection of integrons and antibiotic-resistance genes in *Salmonella enterica* serovar Typhimurium isolates with resistance to ampicillin and variable susceptibility to amoxicillin-clavulanate. *Int J Antimicrob Agents* 24:327-333.
 54. Pardos de la Gandara M, Seral C, Castillo García J, Rubio Calvo C, Weill FX (2011) Prevalence and characterization of extended-spectrum beta-lactamases-producing *Salmonella enterica* isolates in Saragossa, Spain (2001-2008) *Microb Drug Resist* 17: 207-213.
 55. Ricci V, Tzakas P, Buckley A, Piddock LJ (2006) Ciprofloxacin-resistant *Salmonella enterica* serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. *Antimicrob Agents Chemother* 50: 38–42.
 56. Usui M, Uchiyama M, Iwanaka M, Nagai H, Yamamoto Y, Asai T (2009) Intracellular concentrations of enrofloxacin in quinolone-resistant *Salmonella enterica* sub-species enterica serovar Choleraesuis. *Int J Antimicrob Agents* 34: 592–595.
 57. Eaves DJ, Randall L, Gray DT, Buckley A, Woodward MJ, White AP, Piddock LJ (2004) Prevalence of mutations within the quinolone resistance-determining region of *gyrA*, *gyrB*, *parC*, and *parE* and association with antibiotic resistance in quinolone-resistant *Salmonella enterica*. *Antimicrob Agents Chemother* 48: 4012-4015.
 58. Cloeckaert A, Chaslus-Dancla E (2001) Mechanisms of quinolone resistance in *Salmonella*. *Vet Res* 32: 291-300.
 59. Lindgren MM, Kotilainen P, Huovinen P, Hurme S, Lukinmaa S, Webber MA, Piddock LJ, Siitonen A, Hakanen AJ (2009) Reduced fluoroquinolone susceptibility in *Salmonella enterica* isolates from travelers, Finland. *Emerg Infect Dis* 15: 809–812.
 60. Antunes P, Machado J, Peixe L (2007) Dissemination of sul3-containing elements linked to class 1 integrons with an unusual 3' conserved sequence region among *Salmonella* isolates. *Antimicrob Agents Chemother* 51: 1545-1548.
 61. Antunes P, Machado J, Peixe L (2006) Characterization of antimicrobial resistance and class 1 and 2 integrons in *Salmonella enterica* isolates from different sources in Portugal. *J Antimicrob Chemother* 58: 297.
 62. Antunes P, Mourão J, Pestana N, Peixe L (2011) Leakage of emerging clinically relevant multidrug-resistant *Salmonella* clones from pig farms. *J Antimicrob Chemother* 66: 2028–2032.
 63. Cambray G, Guerout AM, Mazel D (2010) Integrons. *Ann Rev Genet*, 44: 41-166.

64. Lévesque C, Piché L, Larose C, Roy PH (1995) PCR mapping of integrons reveals several novel combinations of resistance genes. *Antimicrob Agents Chemother* 39:185-191.
65. Orman BE, Piñeiro S, Arduino S, Galas M, Melano R, Caffer MI, Sordelli DO, Centron D (2002) Evolution of multi-resistance in nontyphoid *Salmonella* serovars from 1984 to 1998 in Argentina. *Antimicrob Agents Chemother* 46: 3963-3970.
66. Bert F, Branger C, Lambert-Zechovsky N (2002) Identification of PSE and OXA beta-lactamase genes in *Pseudomonas aeruginosa* using PCR-restriction fragment length polymorphism. *J Antimicrob Chemother* 50: 11-18.
67. Sandvang D, Aarestrup FM, Jensen LB (1998) Characterization of integrons and antibiotic resistance genes in Danish multi-resistant *Salmonella* enterica Typhimurium DT104. *FEMS Microbiol Lett* 160: 37-41.
68. Ng LK, Mulvey MR, Martin I, Peters GA, Johnson W (1999) Genetic characterization of antimicrobial resistance in Canadian isolates of *Salmonella* serovar Typhimurium DT104. *Antimicrob Agents Chemother* 43: 3018-3021.
69. Frana TS, Carlson SA, Griffith RW (2001) Relative distribution and conservation of genes encoding aminoglycoside-modifying enzymes in *Salmonella* enterica serotype typhimurium phage type DT104. *Appl Environ Microbiol* 67:445-448.
70. Boyd D, Cloeckaert A, Chaslus-Dancla E, Mulvey MR (2002) Characterization of variant *Salmonella* genomic island 1 multidrug resistance regions from serovars Typhimurium DT104 and Agona. *Antimicrob Agents Chemother* 46: 1714-1722.

Corresponding author

Dr. David Miruka Onyango
Maseno University, Department of Zoology
Molecular Microbiology and Biotechnology Laboratory
Box 333-40105 Maseno, Kenya
Phone: +254 (0) 722660647
Email: dvdonyango7@gmail.com; donyango@maseno.ac.ke

Conflict of interests: No conflict of interests is declared.

RETRACTED